Artivion (NYSE:AORT) SVP Andrew Green Sells 11,480 Shares of Stock

Artivion, Inc. (NYSE:AORT) SVP Andrew Green sold 11,480 shares of the firm’s stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $24.97, for a total transaction of $286,655.60. Following the completion of the transaction, the senior vice president directly owned 40,160 shares of the company’s stock, valued at approximately $1,002,795.20. This trade represents a 22.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Artivion Price Performance

Artivion stock traded up $0.48 during mid-day trading on Friday, reaching $25.13. 547,889 shares of the company’s stock traded hands, compared to its average volume of 599,139. The company has a market cap of $1.23 billion, a price-to-earnings ratio of -358.92 and a beta of 1.25. The stock has a 50 day moving average of $26.25 and a two-hundred day moving average of $28.81. The company has a quick ratio of 2.51, a current ratio of 3.47 and a debt-to-equity ratio of 0.82. Artivion, Inc. has a 12-month low of $19.16 and a 12-month high of $48.25.

Artivion (NYSE:AORT) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.13 EPS for the quarter. The business had revenue of $125.76 million during the quarter, compared to analysts’ expectations of $119.99 million. Artivion had a negative net margin of 0.67% and a positive return on equity of 6.07%. Equities analysts forecast that Artivion, Inc. will post 0.45 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Royal Bank of Canada grew its stake in Artivion by 73.1% in the 1st quarter. Royal Bank of Canada now owns 93,676 shares of the company’s stock worth $3,430,000 after acquiring an additional 39,553 shares in the last quarter. Orbimed Advisors LLC bought a new stake in shares of Artivion during the first quarter valued at approximately $5,530,000. Summit Creek Advisors LLC bought a new stake in shares of Artivion during the second quarter valued at approximately $2,704,000. UBS Group AG boosted its holdings in shares of Artivion by 37.0% in the fourth quarter. UBS Group AG now owns 279,675 shares of the company’s stock valued at $12,756,000 after purchasing an additional 75,606 shares during the period. Finally, Fifth Third Bancorp boosted its holdings in shares of Artivion by 58,029.7% in the first quarter. Fifth Third Bancorp now owns 123,235 shares of the company’s stock valued at $4,513,000 after purchasing an additional 123,023 shares during the period. Hedge funds and other institutional investors own 86.37% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on AORT shares. Canaccord Genuity Group raised their price objective on Artivion from $39.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, August 18th. Stifel Nicolaus set a $45.00 price target on Artivion in a report on Monday, June 1st. Weiss Ratings downgraded Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Needham & Company LLC reaffirmed a “buy” rating and set a $44.00 price objective on shares of Artivion in a research note on Monday, July 20th. Finally, Wall Street Zen cut shares of Artivion from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Artivion presently has an average rating of “Moderate Buy” and a consensus target price of $44.83.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.